Pharmacogenetics of osteoporosis.

[1]  J. Gallagher,et al.  Prevention and treatment of postmenopausal osteoporosis , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  G. Heyburn,et al.  Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report. , 2014, Bone.

[3]  X. Xing,et al.  Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis , 2014, Chinese medical journal.

[4]  N. Watts,et al.  Denosumab in osteoporosis , 2014, Expert opinion on drug safety.

[5]  M. Brandi,et al.  The future of pharmacogenetics for osteoporosis. , 2013, Pharmacogenomics.

[6]  J. Marc,et al.  Osteoporosis pharmacogenomics: recent insights and future perspectives. , 2013, Pharmacogenomics.

[7]  R. Shah,et al.  Personalized medicine: is it a pharmacogenetic mirage? , 2012, British journal of clinical pharmacology.

[8]  G. Kullak-Ublick,et al.  Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment. , 2012, Translational research : the journal of laboratory and clinical medicine.

[9]  Hoon Kim,et al.  The association between polymorphisms in Wnt antagonist genes and bone response to hormone therapy in postmenopausal Korean women , 2012, Menopause.

[10]  Tim D. Spector,et al.  Genetics of osteoporosis from genome-wide association studies: advances and challenges , 2012, Nature Reviews Genetics.

[11]  J. Riancho,et al.  Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates , 2010, The Pharmacogenomics Journal.

[12]  Daniel L. Koller,et al.  Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture , 2012, Nature Genetics.

[13]  Yufeng Shen,et al.  Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. , 2012, The oncologist.

[14]  B. Stieger,et al.  Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene , 2012, Journal of Translational Medicine.

[15]  S. Chanprasertyothin,et al.  Effects of differences in polymorphism of gene encoding enzyme faenesyl diphosphate synthase (FDPS), rs2297480, on bone mineral density and biochemical markers of bone turnover in Thai postmenopausal women. , 2011, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[16]  M. Dimopoulos,et al.  CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma , 2011, Haematologica.

[17]  Hoon Kim,et al.  Association between Wnt signaling pathway gene polymorphisms and bone response to hormone therapy in postmenopausal Korean women , 2011, Menopause.

[18]  M. Brandi,et al.  Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. , 2011, Frontiers in bioscience.

[19]  W. Figg,et al.  A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer , 2010, Therapeutics and clinical risk management.

[20]  Sundeep Khosla,et al.  Update on estrogens and the skeleton. , 2010, The Journal of clinical endocrinology and metabolism.

[21]  A. LaCroix,et al.  Lasofoxifene in postmenopausal women with osteoporosis. , 2010, The New England journal of medicine.

[22]  Sun Wook Cho,et al.  Genetic Polymorphism of Geranylgeranyl Diphosphate Synthase (GGSP1) Predicts Bone Density Response to Bisphosphonate Therapy in Korean Women , 2010, Yonsei medical journal.

[23]  B. J. Gates,et al.  Review of osteoporosis pharmacotherapy for geriatric patients. , 2009, The American journal of geriatric pharmacotherapy.

[24]  Zhenlin Zhang,et al.  [Osteoprotegerin gene polymorphism and therapeutic response to alendronate in postmenopausal women with osteoporosis]. , 2009, Zhonghua yi xue za zhi.

[25]  M. Bogataj,et al.  Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics. , 2009, British journal of clinical pharmacology.

[26]  P. Dayer,et al.  Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates , 2009, Drug safety.

[27]  B. Steele,et al.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study , 2009, Osteoporosis International.

[28]  S. Ralston,et al.  LRP5 Polymorphisms and Response to Risedronate Treatment in Osteoporotic Men , 2009, Calcified Tissue International.

[29]  J. S. San Miguel,et al.  Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. , 2008, Blood.

[30]  C. Christiansen,et al.  Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis* , 2008 .

[31]  D. Lorich,et al.  Low-Energy Femoral Shaft Fractures Associated With Alendronate Use , 2008, Journal of orthopaedic trauma.

[32]  T. Howe,et al.  An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? , 2008, Injury.

[33]  C. Christiansen,et al.  Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2‐Yr Results of a Randomized, Double‐Blind, Placebo‐, and Active‐Controlled Study , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  G. Luleci,et al.  Effects of hormone replacement therapy on bone mineral density in Turkish patients with or without COL1A1 Sp1 binding site polymorphism , 2007, The journal of obstetrics and gynaecology research.

[35]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate: Review of Statistical Analysis , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  K. Calis,et al.  Zoledronic acid and secondary prevention of fractures. , 2007, The New England journal of medicine.

[37]  R. Parker,et al.  Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women. , 2007, Maturitas.

[38]  O. Johnell,et al.  An estimate of the worldwide prevalence and disability associated with osteoporotic fractures , 2006, Osteoporosis International.

[39]  P. Marie,et al.  Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation , 2006, Current opinion in rheumatology.

[40]  J. Knezetic,et al.  Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. , 2006, Maturitas.

[41]  T. Yahata,et al.  Association between single nucleotide polymorphisms of estrogen receptor alpha gene and efficacy of HRT on bone mineral density in post-menopausal Japanese women. , 2005, Human reproduction.

[42]  I. Heilberg,et al.  Estrogen Receptor (ER) Gene Polymorphism May Predict the Bone Mineral Density Response to Raloxifene in Postmenopausal Women on Chronic Hemodialysis , 2005, Renal failure.

[43]  C. Francescutti,et al.  Risk Factors Correlated with Post-operative Mortality for Hip Fracture Surgery in the Elderly: A Population-based Approach , 2005, European Journal of Epidemiology.

[44]  F. Manguso,et al.  BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial , 2005, Osteoporosis International.

[45]  M. Rogers.  New insights into the molecular mechanisms of action of bisphosphonates. , 2003, Current pharmaceutical design.

[46]  C. Nappi,et al.  Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. , 2003, Human reproduction.

[47]  Yusuke Nakamura,et al.  Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190 562 genetic variations in the human genome , 2002, Journal of Human Genetics.

[48]  G. Guyatt,et al.  IV. Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal Osteoporosis , 2002 .

[49]  R. Komel,et al.  No major effect of estrogen receptor beta gene RsaI polymorphism on bone mineral density and response to alendronate therapy in postmenopausal osteoporosis , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[50]  I. Hassinen,et al.  Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. , 2002, Molecular pharmacology.

[51]  G. Blake,et al.  COLIA1 Sp1 Polymorphism Predicts Response of Femoral Neck Bone Density to Cyclical Etidronate Therapy , 2002, Calcified Tissue International.

[52]  P. Delmas,et al.  Reconstructing the skeleton with intermittent parathyroid hormone , 2001, Trends in Endocrinology & Metabolism.

[53]  R. Honkanen,et al.  The Protective Effect of Hormone‐Replacement Therapy on Fracture Risk Is Modulated by Estrogen Receptor α Genotype in Early Postmenopausal Women , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[54]  D. Kiel,et al.  A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. , 2000, The American journal of medicine.

[55]  F. Rousseau,et al.  The Association Between Heel Ultrasound and Hormone Replacement Therapy Is Modulated by a Two‐Locus Vitamin D and Estrogen Receptor Genotype , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[56]  S. Chanprasertyothin,et al.  Oestrogen‐receptor‐α gene polymorphism affects response in bone mineral density to oestrogen in post‐menopausal women , 2000 .

[57]  M. Tomita,et al.  Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. , 1999, American journal of obstetrics and gynecology.

[58]  R. Komel,et al.  VDR Genotype and Response to Etidronate Therapy in Late Postmenopausal Women , 1999, Osteoporosis International.

[59]  J. Eisman,et al.  Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial , 1998, Annals of Internal Medicine.

[60]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.